Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
166Ho-DOTMP Plus Melphalan for Refractory Multiple Myeloma
NCT00083564Phase 3Terminated
- Sponsor
- Poniard Pharmaceuticals, Inc.
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Holmium-166-DOTMP in multiple myeloma (MM) (2 arms), sponsored by Poniard Pharmaceuticals, Inc. Primary endpoint: Complete Response. Started Mar 2004; status: terminated.
02
Drugs
Holmium-166-DOTMP
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00083564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083564.